Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

被引：0
|
作者：
Liu, Delong [1 ]
Matloub, Yousif [2 ]
Mulchopadhyay, Jaydip [2 ]
Liu, David [2 ]
Goldberg, Stuart L. [3 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[3] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：741 / 741
页数：1
相关论文
共 50 条
  • [41] Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 740 - 741
  • [42] Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Bixby, Dale L.
    Flinn, Ian
    O'Hare, Thomas J.
    Hu, Simin
    Rivera, Victor M.
    Clackson, Timothy Piers
    Conlan, Maureen G.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W. N.
    Mauro, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    O'Brien, Susan
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Daver, Naval G.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Skinner, Jeff
    Konopleva, Marina
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [44] Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
    Naqvi, Kiran
    Cortes, Jorge
    Skinner, Jeffrey
    Jabbour, Elias
    Pemmaraju, Naveen
    Borthakur, Gautam
    Estrov, Zeev
    Bose, Prithviraj
    Thompson, Philip
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S15 - S16
  • [45] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib
    Al-Ameri, Ali M.
    Kantarjian, Hagop
    Burton, Elizabeth
    O'Brien, Susan
    Ravandi, Farhad
    Borthakur, Gautam
    Walker, Brenda
    Rios, Mary Bath
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1275 - 1275
  • [47] 30Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice
    Cortes, Jorge E.
    Chen, Clara
    Mauro, Michael J.
    Sen, Ginny P.
    Gajavelli, Srikanth
    Davis, Catherine
    Goldberg, Stuart L.
    BLOOD, 2018, 132
  • [48] TYROSINE KINASE INHIBITOR (TKI) SWITCHING: EXPERIENCE FROM SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS IN CLINICAL PRACTICE
    Hehlmann, R.
    Cortes, J.
    Gambacorti-Passerini, C.
    Goldberg, S. L.
    Khoury, H. J.
    Mauro, M.
    Michallet, M.
    Mohamed, H.
    Powell, T.
    Paquette, R.
    Simonsson, B.
    Subar, M.
    Zyczynski, T.
    HAEMATOLOGICA, 2014, 99 : 328 - 329
  • [49] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
    Lipton, Jeffrey H.
    Chuah, Charles
    Guerci-Bresler, Agnes
    Rosti, Gianantonio
    Simpson, David
    Assouline, Sarit
    Etienne, Gabriel
    Nicolini, Franck E.
    Le Coutre, Philipp
    Clark, Richard
    Stenke, Leif
    Andorsky, David
    Oehler, Vivian
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Baccarani, Michele
    Cortes, Jorge E.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Talpaz, Moshe
    Deininger, Michael W.
    BLOOD, 2014, 124 (21)
  • [50] Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)
    Liu-Dumlao, Theresa
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    Burger, Jan A.
    Alvarado, Yesid
    Burton, Elizabeth M.
    Trinh, Long Xuan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1188 - 1188
12345